199 related articles for article (PubMed ID: 34036168)
21. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
[TBL] [Abstract][Full Text] [Related]
22. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
[TBL] [Abstract][Full Text] [Related]
23. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective.
Schumacher L; Leino AD; Park JM
Pharmacotherapy; 2021 Jan; 41(1):103-118. PubMed ID: 33131078
[TBL] [Abstract][Full Text] [Related]
24. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
[TBL] [Abstract][Full Text] [Related]
25. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
26. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation.
Shuker N; Shuker L; van Rosmalen J; Roodnat JI; Borra LC; Weimar W; Hesselink DA; van Gelder T
Transpl Int; 2016 Nov; 29(11):1158-1167. PubMed ID: 27188932
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.
Jung HY; Cho SY; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
J Korean Med Sci; 2019 Apr; 34(12):e103. PubMed ID: 30940998
[TBL] [Abstract][Full Text] [Related]
29. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
[TBL] [Abstract][Full Text] [Related]
30. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
[TBL] [Abstract][Full Text] [Related]
31. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
Chakrabarti P; Wong HY; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Hakala TR; Fung JJ; Simmons RL; Starzl TE; Shapiro R
Transplantation; 2000 Sep; 70(5):760-4. PubMed ID: 11003353
[TBL] [Abstract][Full Text] [Related]
32. Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA-Sensitized Patients Given Tacrolimus Once or Twice Daily During the First 2 Years After Kidney Transplant.
Hage V; Ferrandiz I; Béllière J; Esposito L; Hebral AL; Cointault O; Del Bello A; Kamar N
Exp Clin Transplant; 2019 Jun; 17(3):313-319. PubMed ID: 30602364
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
34. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
35. Influence of Tacrolimus Intrapatient Variability on Allograft Rejection Frequency and Survival Following Liver Transplantation.
Soares ME; Costa G; Guerra L; Morais MC; Vaz N; Codes L; Bittencourt PL
Ther Drug Monit; 2024 Mar; ():. PubMed ID: 38648652
[TBL] [Abstract][Full Text] [Related]
36. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
[TBL] [Abstract][Full Text] [Related]
37. High Intrapatient Variability of Tacrolimus Levels and Outpatient Clinic Nonattendance Are Associated With Inferior Outcomes in Renal Transplant Patients.
Goodall DL; Willicombe M; McLean AG; Taube D
Transplant Direct; 2017 Aug; 3(8):e192. PubMed ID: 28795143
[TBL] [Abstract][Full Text] [Related]
38. Lower Time in Therapeutic Range Relates to a Worse Kidney Graft Outcome.
Barreda P; Cañamero L; Boya M; García-Saiz MDM; Valero R; Belmar L; Kislikova M; De Cos MA; Ruiz JC; Rodrigo E
Transplant Proc; 2022 Nov; 54(9):2446-2449. PubMed ID: 36272833
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus monitoring parameters are not associated with acute cellular rejection following lung transplantation.
Kao CC; Segraves J; Parulekar AD
Eur J Clin Pharmacol; 2021 Jan; 77(1):63-69. PubMed ID: 32803287
[TBL] [Abstract][Full Text] [Related]
40. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
